I'm not sure what CELG or ONXX would gain by running a combo trial in 3rd line with someone else's investigational drug. This is especially true since the onus is on ARRY to prove the value of their drug, rather than CELG / ONXX trying to fight over a few more patients in the third line.
Yes there is still a long way for 520 to go and I am not assuming anything. But, if it pans out and adds meaningfully as part of a combo (be it with kyprolis, pom, or whatever), wouldn't a company have an incentive to utlize it as a combo, as opposed to having a competitor utilize it with a competing drug as part of a superior regimen? Don't understand why there wouldn't be an incentive for the established company to maintain its edge in such a scenario. All hypothetical at this stage, obviously.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.